Animas Upgrades Complaint Handling Program After Warning Letter
This article was originally published in The Gray Sheet
Executive Summary
Animas says it has improved its complaint handling and corrective and preventive action programs substantially since receiving an FDA warning letter in February
You may also be interested in...
Animas Looks Forward To Continuous Glucose Monitoring As Market Crowds
Animas' hoped-for launch of the GlucoWatch G3 continuous blood glucose monitoring system in the first half of 2006 will depend upon resolution of issues cited in a February warning letter from FDA
Animas Looks Forward To Continuous Glucose Monitoring As Market Crowds
Animas' hoped-for launch of the GlucoWatch G3 continuous blood glucose monitoring system in the first half of 2006 will depend upon resolution of issues cited in a February warning letter from FDA
Animas Draws Warning Letter For MDR-Related Lapses, QSR Gaps
FDA is concerned with insulin pump maker Animas' processes for handling complaints and fixing products